Skip to main content

Table 5 Post-treatment low-density lipoprotein cholesterol levels (mmol/L) in randomized controlled trials

From: Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials

Interventions No. of trials [references] No. of participants Weighted mean difference (95% confidence interval) P value
RYR vs. no intervention/placebo     
Zhibituo vs. no intervention 1 [22] 62 -0.16 (-0.71 to 0.39) 0.57
RYR supplement vs. placebo 1 [7] 83 -1.04 (-1.38 to -0.70) < 0.00001
Xuezhikang vs. placebo 4 [8, 24–26] 323 -0.74 (-0.93 to -0.55) < 0.00001
Zhibituo vs. placebo 1 [29] 205 -0.20 (-0.53 to 0.13) 0.24
RYR vs. statins     
Xuezhikang vs. simvastatin 13 [6, 30–34, 36–38, 40–43] 1238 0.14 (-0.05 to 0.33)* 0.14
Xuezhikang vs. pravastatin 7 [44–50] 587 -0.09 (- 0.20 to 0.02)* 0.11
Xuezhikang vs. lovastatin 3 [51–53] 191 0.00 (- 0.26 to 0.27) 0.98
Xuezhikang vs. atorvastatin 1 [54] 60 0.20 (-0.10 to 0.50) 0.19
Xuezhikang vs. fluvastatin 1 [55] 118 0.14 (-0.10 to 0.38) 0.26
Zhibituo vs. simvastatin 8 [32, 56–62] 601 0.22 (0.04 to 0.39) 0.02
Zhibituo vs. provastatin 1 [22] 62 -0.11 (-0.60 to 0.38) 0.66
Zhibituo vs. lovastatin 1 [57] 45 0.03 (-0.30 to 0.36) 0.86
RYR vs. non-statin drugs     
Xuezhikang vs. inositol nicotinate 4 [66–68, 70] 299 -0.63 (-0.96 to -0.30) 0.0002
Xuezhikang vs. fenofibrate 3 [32, 74, 76] 220 -0.10 (-1.05 to 0.85)* 0.84
Xuezhikang vs. gemfibrozil 3 [77–79] 152 -0.34 (-0.58 to -0.10) 0.005
Xuezhikang vs. fish oils 1 [81] 95 -0.89 (-1.41 to -0.37) 0.0008
Xuezhikang vs. conjugated estrogens 1 [85] 44 -0.10 (-0.43 to 0.23) 0.55
Xuezhikang vs. biphenalbid 1 [87] 64 -0.06 (-0.32 to 0.20) 0.65
Zhibituo vs. fish oils 5 [97–101] 489 -0.57 (-0.70 to -0.45) < 0.00001
Zhibituo vs. fenofibrate 1 [32] 90 0.3 1 (0.04 to 0.58) 0.02
RYR vs. RYR     
Xuezhikang vs. Zhibituo 5 [32, 106, 108, 109, 111] 628 -0.08 (-0.18 to 0.02) 0.12
  1. * Random effects model